ADORA3 and prostate carcinoma: Previous studies have found that ADORA3 is highly expressed in a variety of malignant tumors, including melanoma, breast cancer, prostate cancer, liver cancer, pancreatic cancer, lung cancer, lymphoma, glioblastoma, and malignant pleural mesothelioma [54,55,56].